TapewireFind a company

organization · Reporting owner

Foresite Capital Fund IV, L.P.

Disclosed activity across 5 companies

Tapewire entity
67425
SEC CIK
0001704131

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
10x Genomics, Inc.TXG · Entity 217210% ownerSeptember 11, 2019September 12, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2019-09-11 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: Each share of Series A-2 Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series A-2 Convertible Preferred Stock.

F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Series B Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2019-09-11 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock.

F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Series B Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2019-09-11 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock.

F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2019-09-11 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock.

F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2019-09-11 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance Not disclosed

F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock.

F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-2 Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series A-2 Convertible Preferred Stock.

F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock.

F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock.

F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2020-03-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote1,369,938 Reported balance After 2020-02-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-02-27 · Sale · Disposed 302,776 · Balance 1,369,938

F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,925,020 Reported balance After 2020-02-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-02-27 · Sale · Disposed 425,457 · Balance 1,925,020

F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,229,633 Reported balance After 2020-02-27 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2020-02-27 · Sale · Disposed 271,767 · Balance 1,229,633

F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2021-11-01 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2021-11-01 · Other · Disposed 1,954,904 · Balance 0

F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote8,276 Reported balance After 2021-11-01 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2021-11-01 · Other · Acquired 8,276 · Balance 8,276

F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote3,399,034 Reported balance Holding disclosure · report date 2021-11-01 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 3,399,034

F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,258,243 Reported balance Holding disclosure · report date 2021-11-01 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,258,243

F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote1,340,878 Reported balance After 2026-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-02-04 · Conversion · Acquired 1,340,878 · Balance 1,340,878

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,676,399 Reported balance After 2026-02-04 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2026-02-04 · Conversion · Acquired 335,521 · Balance 1,676,399

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,714,254 Reported balance After 2026-02-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 1,714,254

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,943,682 Reported balance After 2026-02-04 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2026-02-04 · Conversion · Acquired 229,428 · Balance 1,943,682

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote697,885 Reported balance After 2026-02-04 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2026-02-04 · Conversion · Acquired 697,885 · Balance 697,885

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote735,740 Reported balance After 2026-02-04 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 735,740

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote737,366 Reported balance After 2026-02-04 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2026-02-04 · Conversion · Acquired 1,626 · Balance 737,366

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote804,573 Reported balance After 2026-02-04 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2026-02-04 · Conversion · Acquired 67,207 · Balance 804,573

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,263,428 Reported balance After 2026-02-04 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2026-02-04 · Conversion · Acquired 458,855 · Balance 1,263,428

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote348,942 Reported balance After 2026-02-04 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2026-02-04 · Conversion · Acquired 348,942 · Balance 348,942

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote386,797 Reported balance After 2026-02-04 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 386,797

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote387,719 Reported balance After 2026-02-04 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 12 · 2026-02-04 · Conversion · Acquired 922 · Balance 387,719

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote425,852 Reported balance After 2026-02-04 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 13 · 2026-02-04 · Conversion · Acquired 38,133 · Balance 425,852

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote408,725 Reported balance After 2026-02-04 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 14 · 2026-02-04 · Conversion · Acquired 408,725 · Balance 408,725

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,318,983 Reported balance After 2026-02-04 transaction · row 15 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 15 · 2026-02-04 · Purchase · Acquired 55,555 · Balance 1,318,983

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2026-02-04 · Conversion · Disposed 10,000,000 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 17 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 17 · 2026-02-04 · Conversion · Disposed 2,502,252 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 18 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 18 · 2026-02-04 · Conversion · Disposed 5,204,684 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 19 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 19 · 2026-02-04 · Conversion · Disposed 2,602,342 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 20 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 20 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 21 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 21 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 22 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 22 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 23 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 23 · 2026-02-04 · Conversion · Disposed 3,048,192 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 24 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 24 · 2026-02-04 · Conversion · Disposed 12,123 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 25 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 25 · 2026-02-04 · Conversion · Disposed 6,878 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 26 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 26 · 2026-02-04 · Conversion · Disposed 501,219 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 27 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 27 · 2026-02-04 · Conversion · Disposed 284,392 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 28 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 28 · 2026-02-04 · Conversion · Disposed 1,711,025 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2026-02-04 transaction · row 29 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 29 · 2026-02-04 · Conversion · Disposed 3,422,051 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14IndirectSee Footnote17,092 Reported balance Holding disclosure · report date 2026-02-04 · row 30 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 30 · Balance 17,092

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14IndirectSee Footnote34,185 Reported balance Holding disclosure · report date 2026-02-04 · row 31 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 31 · Balance 34,185

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-04-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-04-03 · Disposition to issuer · Disposed 9,671,643 · Balance 0

F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-04-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-04-03 · Disposition to issuer · Disposed 3,525,957 · Balance 0

F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-04-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-04-03 · Disposition to issuer · Disposed 520,711 · Balance 0

F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries D Preferred Stock · Derivative 3,422,051 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 29

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 458,855 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries D Preferred Stock · Derivative 1,711,025 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 28

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 229,428 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries C-1 Preferred Stock · Derivative 284,392 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 27

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 38,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries C-1 Preferred Stock · Derivative 501,219 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 26

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 67,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries C Preferred Stock · Derivative 6,878 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 25

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 922 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries C Preferred Stock · Derivative 12,123 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 24

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,626 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries B-1 Preferred Stock · Derivative 3,048,192 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 23

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 408,725 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F5 · ownership.nature: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries B-1 Preferred Stock · Derivative 282,317 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 22

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 37,855 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries B-1 Preferred Stock · Derivative 282,317 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 21

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 37,855 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries B-1 Preferred Stock · Derivative 282,317 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 20

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 37,855 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries A-1 Preferred Stock · Derivative 2,602,342 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 19

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 348,942 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries A-1 Preferred Stock · Derivative 5,204,684 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 18

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 697,885 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries A-1 Preferred Stock · Derivative 2,502,252 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 17

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 335,521 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries A Preferred Stock · Derivative 10,000,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 16

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,340,878 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 PurchaseCommon Stock 55,555 $18.00 $999,990.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 15

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,318,983

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 408,725 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 14

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 408,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F5 · ownership.nature: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 38,133 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 13

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 425,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 922 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 12

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 387,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 37,855 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 11

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 386,797

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 348,942 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 10

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 348,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 458,855 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 9

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,263,428

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 67,207 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 8

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 804,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 1,626 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 7

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 737,366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 37,855 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 6

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 735,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 697,885 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 5

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 697,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 229,428 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 4

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,943,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 37,855 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 3

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,714,254

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 335,521 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 2

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,676,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 19:37 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 1,340,878 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 1

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner

Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,340,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 14:15 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 Disposition to issuerCommon Stock 520,711 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-24-044187 · tm2411018-1_4seq1.xml · nonDerivative · entry 3

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F4 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 14:15 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 Disposition to issuerCommon Stock 3,525,957 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-24-044187 · tm2411018-1_4seq1.xml · nonDerivative · entry 2

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 14:15 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 Disposition to issuerCommon Stock 9,671,643 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-24-044187 · tm2411018-1_4seq1.xml · nonDerivative · entry 1

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
May 08, 2023 Filed May 10, 2023 17:42 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 PurchaseCommon Stock 229,044 $2.80 $641,323.20
Disclosure

SEC source: 0001209191-23-028527 · doc4.xml · nonDerivative · entry 2

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 520,711

F2 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
May 08, 2023 Filed May 10, 2023 17:42 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 PurchaseCommon Stock 1,550,956 $2.80 $4,342,676.80
Disclosure

SEC source: 0001209191-23-028527 · doc4.xml · nonDerivative · entry 1

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,525,957

F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
February 17, 2023 Filed Feb 22, 2023 14:49 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 OtherCommon Stock 1,100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-011565 · doc4.xml · nonDerivative · entry 1

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,975,001

F1 · kind: On February 17, 2023, the Issuer completed the acquisition of Kinnjiu Biompharma, Inc. (the "Kinnjiu Acquisition"). Foresite Capital Fund V, L.P. ("Fund V") was a shareholder of Kinnjiu Biompharma, Inc. and, as a result of the Kinnjiu Acquisition, Fund V received a combination of cash and 1,100,000 shares of the Issuer's Common Stock.

F2 · shares: Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757.

F2 · price: Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757.

F3 · ownership.nature: The shares are owned directly by Fund V. Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:17 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 OtherCommon Stock 8,276 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 4

Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner

Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Tananbaum James B. · CIK 0001581754 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,276

F5 · kind: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F6 · ownership.nature: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:17 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 OtherCommon Stock 1,954,904 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 1

Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner

Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Tananbaum James B. · CIK 0001581754 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries C Preferred Stock · Derivative 48,376 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 12

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 48,538 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries C Preferred Stock · Derivative 145,128 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 11

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 145,614 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries C Preferred Stock · Derivative 157,222 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 10

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 157,748 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries B Preferred Stock · Derivative 18,641 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 9

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 18,641 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries B Preferred Stock · Derivative 55,922 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 8

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 55,922 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries B Preferred Stock · Derivative 2,666,002 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 7

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,666,002 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries A Preferred Stock · Derivative 99,488 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 6

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 99,488 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries A Preferred Stock · Derivative 298,465 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 5

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 298,465 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionSeries A Preferred Stock · Derivative 6,347,893 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 4

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 6,347,893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionCommon Stock 166,667 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 3

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 291,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionCommon Stock 500,001 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 2

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 875,001

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 ConversionCommon Stock 9,171,643 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 1

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,671,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document
December 03, 2020 Filed Dec 4, 2020 20:57 UTC Kinnate Biopharma Inc. KNTE · Entity 92187 GrantCommon Stock 125,000 $20.00 $2,500,000.00
Disclosure

SEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 3

Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner

Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 125,000

F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.